Cancer Research SABCS EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 66, 10365, November 1, 2006. Published Online First October 23, 2006;
doi: 10.1158/0008-5472.CAN-06-2977
© 2006 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-06-2977v1
66/21/10365    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qian, C.-N.
Right arrow Articles by Teh, B. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qian, C.-N.
Right arrow Articles by Teh, B. T.

Molecular Biology, Pathobiology, and Genetics

Preparing the "Soil": The Primary Tumor Induces Vasculature Reorganization in the Sentinel Lymph Node before the Arrival of Metastatic Cancer Cells

Chao-Nan Qian1,5, Bree Berghuis2, Galia Tsarfaty3, MaryBeth Bruch3, Eric J. Kort4, Jon Ditlev1, Ilan Tsarfaty3, Eric Hudson2, David G. Jackson6, David Petillo1, Jindong Chen1, James H. Resau2 and Bin Tean Teh1

Laboratories of 1 Cancer Genetics, 2 Analytical, Cellular, and Molecular Microscopy, 3 Molecular Oncology, and 4 Molecular Epidemiology, Van Andel Research Institute, Grand Rapids, Michigan; 5 Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China; and 6 Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Requests of reprints: Chao-Nan Qian, Laboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick Avenue Northeast, Grand Rapids, MI 49503. Phone: 616-234-5538; Fax: 616-234-5539; E-mail: chaonan.qian{at}vai.org or Bin Tean Teh, Laboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick Avenue Northeast, Grand Rapids, MI 49503. Phone: 616-234-5296; Fax: 616-234-5297; E-mail: bin.teh{at}vai.org.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Sentinel lymph node (SLN) metastasis is the first step in the spreading of cancer in many malignancies. Tumor-reactive lymphadenopathy in SLNs has been observed for decades, but alterations of the lymphatic channels and vasculature in these nodes before the arrival of metastatic tumor cells remain unexplored. Using animal models, we show here that, before the establishment of metastasis in the SLN, there are reorganizations of the lymphatic channels and the vasculature. The node becomes a functional blood vessel–enriched and lymph vessel/sinus-enriched organ before metastasis. The enlargement of the lymph sinuses is correlated with the primary tumor weight. The newly emerged functional blood vessels develop from high endothelial venules (HEV), in which the proliferation rate of the endothelial cells is also significantly increased. Similar alterations of the HEVs are also characterized in the axillary lymph nodes from human breast cancer patients without the evidence of metastasis. These findings support the hypothesis that modification of the microenvironment for a secondary tumor (i.e., vasculature reorganization in the SLN) can be initiated by a primary tumor before and independent of the physical presence of metastatic cancer cells. (Cancer Res 2006; 66(21): 10365-76)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The most important survival predictor in patients with head and neck cancers is cervical lymph node metastasis, regardless of extension of the primary tumor (1). Detection of lymph node metastasis is therefore important for tumor staging and therapy planning. Current imaging approaches to evaluate lymph node metastasis mainly rely on the size and the shape of the involved lymph node, and controversial interpretations of these imaging results remain due to the limited knowledge of the angiogenesis and lymphangiogenesis within the lymph node.

It has been known for decades that regional lymph nodes draining tumor areas may be enlarged without evidence of metastasis. The term for this condition is tumor-reactive lymphadenopathy (2). However, the processes of lymphangiogenesis and angiogenesis in tumor-reactive lymphadenopathy are not well understood. Angiogenesis is essential to the growth and metastasis of solid tumors (3). Recently, intratumoral lymphangiogenesis has been characterized in head and neck carcinomas, related to regional cervical lymph node metastasis (4, 5). Increased expression of vascular endothelial growth factor (VEGF)-C, which can induce lymphangiogenesis, is also correlated with regional lymph node metastasis of cancer cells in both animal model and human tumors (6, 7). Expression of platelet-derived growth factor in murine fibrosarcoma cells can induce tumor lymphangiogenesis, leading to enhanced metastasis in lymph nodes (8). Lymphangiogenesis in the lymph nodes induced by VEGF-A contributes to cancer metastasis (9).

Nasopharyngeal carcinoma (NPC) has the highest incidence rate of lymph node metastasis among head and neck cancers (10, 11). In breast cancer, axillary lymph node involvement is a significant prognostic factor (12, 13), although 20% to 30% of node-negative patients will develop distant metastases within 10 years (14). To characterize the process of lymph node metastasis, we established a spontaneous lymph node metastasis animal model by using a human, poorly differentiated NPC cell line, CNE-2 (15), and the murine breast cancer cell line DA3. The premetastatic alterations of the sentinel lymph node (SLN), which receives direct lymphatic drainage from the tumor lesion (16), were analyzed. Human axillary lymph nodes from breast cancer patients were used to confirm the findings from the animal models.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell culture and clone selection. The human NPC cell line CNE-2 and its clones were maintained in DMEM supplemented with 10% fetal bovine serum (FBS). The individual clones from the CNE-2 parental cell line, each grown from a single cell, were isolated by limited dilution methods.

In vitro migration and invasion assays. For migration assays, 5.0 x 104 NPC cells in 500 µL serum-free DMEM was added to the cell culture inserts with an 8-µm microporous filter without extracellular matrix coating (Becton Dickinson Labware, Bedford, MA). DMEM containing 10% FBS was added to the bottom chamber. After 18 hours of incubation, the cells on the lower surface of the filter were fixed and stained followed by microscopic examination. The number of cells in five random optical fields (x200 magnification) from triplicate filters was averaged. For in vitro invasion assays, the inserts of the chambers to which the cells were seeded were coated with Matrigel (Becton Dickinson Labware).

Animals and spontaneous lymph node metastasis assay. Female BALB/c mice and athymic BALB/c nu/nu mice (5-6 weeks old) were maintained in the vivarium of the Van Andel Research Institute (VARI; Grand Rapids, MI). All of the animal studies were conducted under protocols approved by the Institutional Animal Care and Use Committee of VARI.

Tumor cells (8 x 104 in 20 µL Hank's solution) were injected s.c. into the footpad of left hind limb of each nude mouse. On the terminal day, the primary tumor weight was calculated by subtracting the weight of the foot without tumor from the weight of foot carrying the primary tumor. The popliteal lymph nodes from both hind limbs were isolated using a dissecting microscope. The lymph node volumes were calculated as volume = width x length x height / 2.

To trace the lymph drainage, 10 µL Evan's blue dye (0.4%) in PBS was injected s.c. at the end of the limb 15 minutes before sacrifice.

Real-time quantitative PCR. Single CNE-2 cells were identified by limited dilution method in 96-well plates. Total RNA from cells and lymph nodes was extracted using the High Pure RNA Tissue kit (Roche Applied Science, Penzberg, Germany). To prove the validity of this method in identifying a few cancer cells in the lymph node, varying numbers of cancer cells were combined with a certain number of normal popliteal lymph nodes for homogenization. Briefly, tumor cell suspension in culture medium was plated into 96-well plates. Four hours later, the cell number was counted, and 100 µL lysis/binding buffer was added into each well. The lysate was then transferred to a tube containing a certain number of fresh-frozen popliteal lymph nodes from normal mice. Another 300 µL lysis/binding buffer was then added followed by homogenization. Specific primers for human hypoxanthine phosphoribosyltransferase (HPRT) were used (17). The PCR products were continuously measured with an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Forster City, CA) during 50 cycles. The experiments were done in duplicate, and the average of the two samples was calculated.

Ultrasonography and image analyses. Blood flow in the popliteal lymph node was detected in vivo using the Acuson Sequoia 512 (Mountain View, CA) instrument with a 15L8 (15 MHz) linear transducer (18). Mice were anesthetized using continuous inhalation of isoflurane. Ultrasonography was done on the popliteal lymph node 6 to 26 days after tumor cell inoculation into the footpad. No detectable popliteal lymph node was found in the hind limbs of normal healthy mice or in the right hind limbs of the mice carrying left hind footpad tumors. Any sentinel popliteal lymph nodes with histologically verified metastases were excluded from the analyses. The blood flow in large blood vessels of the popliteal lymph node was evaluated by color Doppler ultrasound. The application of contrast medium, which are air bubbles 2 µm in diameter, enables the detection of blood flow in smaller vessels (40-70 µm in diameter). First-pass, low-intensity, nondestructive contrast medium-enhanced ultrasound imaging was done using Definity Perflutren Lipid Microspheres (Bristol-Myers Squibb Medical Imaging, Inc.) by tail-vein injection at 15 µg/mouse. Contrast medium ultrasound imaging analysis was done using UIA dedicated functional molecular imaging analysis software (iLAB's Israel).

Histologic evaluation and immunohistochemical and immunofluorescent staining. Paraffin-embedded human lymph node tissues were obtained from the Shared Pathology Informatics Network at VARI (19).

Mouse lymph nodes were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at 3 µm throughout the lymph node. To exclude lymph nodes containing micrometastases, H&E staining and histologic examination were done on all of the rest of the continuous tissue sections from a whole lymph node after several sections were selected for immunohistochemical staining. To quantify the lymph vessel/sinus area, the largest H&E-stained cross-section of each nonmetastatic lymph node was used for image analyses. Rat anti-mouse CD31 monoclonal antibody (mAb; Research Diagnostics Inc., Concord, MA), the rabbit anti-mouse LYVE-1 antibody (prepared as described; ref. 20), the purified rat anti-mouse MECA-79 (PNAd) antibody (BD PharMingen), and the mouse anti-human CD31 (JC70A, DAKO, Carpinteria, CA) mAb were used at a dilution of 1:50. The mouse anti-human CD34 (QBEnd10, DAKO) mAb was used at a dilution of 1:100. The anti-mouse MECA-79 antibody reacts with both mouse and human PNAd carbohydrate antigen. The proteinase K (DAKO) antigen retrieval method was applied to the staining of CD31 in mouse lymph node. The avidin-biotin complex method Elite kit (Vector Laboratories, Burlingame, CA) was used to detect the primary antibodies followed by 3,3-diaminobenzidine substrate visualization (Vector Laboratories). For immunofluorescent staining, the formalin-fixed, paraffin-embedded tissues were sectioned at 3 µm. Immunoglobulins [FITC-conjugated donkey anti-rabbit, FITC-conjugated goat anti-rat, tetramethylrhodamine isothiocyanate (TRITC)-conjugated donkey anti-rat, and TRITC-conjugated donkey anti-rabbit] at 12 µg/mL (Jackson ImmunoResearch Laboratories, West Grove, PA) were used to detect the primary antibodies.

Endotoxin-induced lymphadenopathy. Lipopolysaccharides from Escherichia coli O127:B8 (Sigma, Saint Louis, MO) were dissolved in PBS (1 mg/mL) and injected into the left hind footpads of 10 BABL/c nude mice at the dosage of 20 µg daily for 20 days. An equal volume of PBS was injected into another group of 10 mice as a vehicle control. After 20 days of injection, the mice were euthanized and the sentinel popliteal lymph nodes were isolated for evaluation.

Proliferation rates of high endothelial venule endothelial cells. Rabbit anti-proliferating cell nuclear antigen (PCNA) polyclonal antibody (Abcam, Inc., Cambridge, MA) and rat anti-mouse MECA79 were applied at 1:100 dilution simultaneously onto the lymph node sections followed by TRITC-conjugated donkey anti-rabbit and FITC-conjugated goat anti-rat secondary antibodies. The nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). At least 200 high endothelial venule (HEV) endothelial cells were randomly counted for each lymph node to calculate the percentage of proliferating endothelial cells. For routine immunohistochemical staining, the rabbit anti-PCNA polyclonal antibody was used at 1:300 dilution.

Image analysis. Image analysis was done using interactive image analysis software developed by our laboratory. Regions positively stained with the HEV marker MECA-79 within the images were identified by combining two binary masks using a logical AND operator. The first mask was generated by identifying pixels that were bright in the yellow image channel [after converting the red, green, and blue (RGB) color image to cyan, magenta, yellow, and black color space]. The second mask was generated by identifying pixels that were dark in the green image channel (from the RGB color space). Pixels that were "bright" or "dark" were automatically identified using the thresholding algorithm of Ridler and Calvard (1978; ref. 21). Small staining artifacts (mainly resulting from nonstaining endothelial nuclei) were removed by applying a two-pixel opening function. Vessels within the binary mask were identified using connected component analysis (22). Several variables for each connected component within the binary mask were then calculated:

  1. The total number of pixels within each component, representing the cross-sectional area of the HEV wall.
  2. The length of edge of each component, representing the sum of the inner and outer circumferences of the vessel wall.
  3. The number of pixels enclosed by the vessel wall, representing the luminal area (if any).
  4. The "longest chord" of the luminal area (if any). This variable was used to correct for nonperpendicular sectioning of the vessels. Once the longest chord is known, the minor axis (i.e., the longest chord perpendicular to the major axis) may be calculated. The area of an ellipse is defined in Eq. 1, where a1 and a2 are half the major and minor axes, respectively [half for the same reason that half the diameter (i.e., the radius) is used for calculating the area of a circle].

Formula 1(1)

Formula 2(2)

Formula 3(3)

Because we measure the area directly (by enumerating pixels within the lumen), we may rearrange this equation to solve for half the minor axis (a2), as given by Eq. 2. With the minor axis known, we may then reconstitute the true perpendicular cross-sectional luminal area (A') using the equation for the area of a circle (Eq. 3).

To calculate total lymph sinus area, the whole H&E-stained section was digitally captured. The lymph sinus regions were identified by segmenting the blue channel of the images of the lymph nodes using the automated thresholding algorithm mentioned above. Artifactual gaps between cells were eliminated using a five-pixel closing function. The number of pixels in the "bright" regions corresponding to the lymph sinus areas was enumerated.

Statistical analysis. The test for equality of proportions was used to evaluate the equivalence of real-time PCR and histopathologic analyses in detection of lymph node metastasis. A two-tailed Student's t test was used for comparing lymph node volumes and the proliferation rates of endothelial cells. The data produced by the image analyses deviated significantly from a normal distribution. Therefore, nonparametric tests were used, including Wilcoxon rank-sum tests for the comparison of means and {chi}2 tests for differences in proportion. Spearman's correlation test was used to assess the relation between tumor weight and lymph vessels/sinuses area. All tests were two tailed. A number that follows the ± sign is a SD.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Spontaneous lymph node metastasis in a mouse model of NPC. There is considerable evidence of heterogeneity in the metastatic population of tumor cells (23–25). We isolated 29 clones from the parental cell line CNE-2 and screened for their migratory and invasive abilities in vitro. Clone-18 statistically produced the greatest migration and invasion when compared with the parental cell line and other clones (Fig. 1A ).


Figure 1
View larger version (39K):
[in this window]
[in a new window]
  		Figure 1. Characterization of CNE-2 cell migration and invasion in vitro and metastasis in vivo. A, the cells that migrated (no Matrigel layer) or invaded (passed through the Matrigel) into the lower chamber in the two-chamber assay were fixed and counted. Columns, mean; bars, SD. B, the lymph node (LN) metastasis rates of the different CNE-2 populations 40 days after the same number of tumor cells (8 x 104 cells) were injected s.c. into the footpad of left hind limb of each nude mouse. Ps are from the comparison of the metastasis rates between the individual clones and the parental CNE-2 cells. C, histologic examination of an H&E-stained section showed a micrometastasis of a CNE-2 tumor embolus (inset) in the subcapsular sinus of a sentinel popliteal lymph node. D, the average primary tumor weights were not different among these cellular populations 40 days after inoculation. E, the lymph node metastasis rates of Clone-18 cells were further evaluated by using the same footpad model at different time points, with 15 mice in each time point group. F, a real-time quantitative PCR method amplifying the human HPRT mRNA was applied to detect human CNE-2 Clone-18 cells mixed with mouse normal popliteal lymph nodes. Curve, the listed formula obtained from normal mouse popliteal lymph nodes added with varying numbers of Clone-18 cells. This method was sensitive enough to detect single cancer cell in one mouse popliteal lymph node. G, a total of 52 sentinel popliteal lymph nodes were harvested 25 days after inoculation of Clone-18 cells into the left hind footpad of the nude mice. All of the lymph nodes were equally divided, with one half used for quantitative PCR and the other half for conventional, thorough, histopathologic evaluation. The test for equality of proportions showed these two methods were equivalent in detection of metastasis.

 
To study the process of spontaneous lymph node metastasis, an animal model was established by injecting CNE-2 tumor cells into the left hind footpad of immunodeficient nude mice, resulting in metastasis to the popliteal lymph node, which is the SLN for this model. Relative to the parental cell line and other clones, Clone-18 had a significantly greater potential of metastasis (Fig. 1B and C), although the primary tumor growth rates were not different among these cell populations (Fig. 1D). Metastases of Clone-18 were observed by day 20 and reached 100% metastatic incidence on day 50 after inoculation of 8 x 104 cells into the hind footpad of the mouse (Fig. 1E). The footpad model was used because (a) there is only a single popliteal lymph node in the anatomic structure of the murine rear leg and (b) the anatomic location of the popliteal lymph node is constant, superficial, and easy to identify by palpation, favoring noninvasive imaging by ultrasonography. To study the histologic alteration before metastasis, we restricted our analyses to the lymph node that contained no CNE-2 micrometastasis as assessed by thorough histologic analysis (Fig. 1C). We proved that the sensitivity of this conventional histopathologic approach was equivalent to that of the real-time quantitative PCR method, which could identify single human cancer cell in a murine lymph node (Fig. 1F and G).

The neovascularization in SLN before metastasis is functional. To evaluate the baseline histology in popliteal lymph nodes before CNE-2 metastasis, the nodes from both hind limbs of the tumor-bearing animals were collected on days 10 to 26 after Clone-18 cells were inoculated into the left hind footpad. Tumor-reactive lymphadenopathy was found to be induced in most of the popliteal SLNs (Fig. 2A and B ). Compared with the contralateral popliteal lymph node and a normal (noninjected animal) popliteal lymph node, the popliteal SLN was significantly enlarged by day 20 after inoculation and before detectable metastasis. The mean volumes for the fresh, unfixed normal (n = 10), contralateral (n = 10), and sentinel (n = 10) popliteal lymph nodes were 2.5 ± 0.8, 2.1 ± 0.8, and 8.3 ± 5.4 mm3, respectively, with statistical significance for the sentinel versus the normal popliteal lymph node (P = 0.008) and for the sentinel versus the contralateral popliteal lymph node (P = 0.005). No significant difference of volume was found between the normal and contralateral lymph nodes.


Figure 2
View larger version (84K):
[in this window]
[in a new window]
  		Figure 2. The newly emerged vasculature in tumor-reactive lymphadenopathy functions as a blood flow carrier. A, autopsy was done after injection of Evan's blue dye. The pictures of the same mouse showed the enlargement of the sentinel popliteal lymph node with more functional blood vessels (arrow) before metastasis. B, the popliteal lymph nodes from another mouse were isolated together with the hilar tissues and transparentized with 80% glycerol. Enrichment of functional blood vessels (red; arrows) and lymphatic vessels/sinuses (blue; arrowheads) was clearly evident in the SLN before metastasis. C, ultrasonography images of the popliteal lymph nodes from a nude mouse carrying CNE-2 Clone-18 cells. The blood flow (red and blue) in the sentinel popliteal lymph node (confined with white arrows) could be detected, whereas it was undetectable in the contralateral popliteal lymph node. The SLN was later proven histologically to be cancer cell–free. D, ultrasonographic images of the popliteal lymph nodes from an immunocompetent BALB/c mouse carrying a syngeneic DA3 tumor in the footpad before metastasis. The blood flow (red and blue) was evident in the SLN (white arrows), with no detectable blood flow in the contralateral lymph node. E, ultrasound contrast medium signal intensity map of a sentinel popliteal lymph node and the contralateral popliteal lymph node in the same mouse, showing the blood flow in small blood vessels within the lymph node at 0, 1, 2, and 3 seconds after injection of the contrast. Circles, area of popliteal lymph node. Increased blood flow was evident in the sentinel popliteal lymph node before metastasis.

 
The enlarged popliteal lymph nodes were enriched in functional blood vessels compared with contralateral lymph nodes (Fig. 2B). By using ultrasonographic, real-time blood flow measurements (26), we found that the blood flow in large blood vessels of the enlarged sentinel popliteal lymph node was increased 20 days after Clone-18 tumor cell inoculation; there was no detectable blood flow in the contralateral popliteal lymph node of the same mouse (Fig. 2C). Moreover, increased blood flow in the popliteal SLN was also found in the immunocompetent BALB/c mice carrying footpad syngeneic DA3 breast adenocarcinoma 15 days after inoculation and before metastasis, again with undetectable blood flow in the contralateral popliteal lymph node (Fig. 2D). After administration of contrast medium, the blood flow in small blood vessels in the popliteal SLN from nude mice carrying Clone-18 cells was clearly detectable by ultrasonography as early as day 17 after tumor cell inoculation, whereas there was no detectable blood flow in the contralateral popliteal lymph node in the same mouse (Fig. 2E). The increase of blood flow in the vessels draining the SLN was also determined (data not shown), and it was consistent with the finding from a s.c. xenograft tumor model in nude mice that the increase in regional blood flow may result from the mobilization of pre-existent latent vessels (27). These data suggested the integration of the SLN vasculature into the adjacent vascular system. All of these functional measurements indicated that the newly emerging vasculature in sentinel popliteal lymph node was functioning before metastasis.

Lymphangiogenesis in SLNs before metastasis. An increase in the number of lymph vessels/sinuses, as well as their level of dilation, was evident in the popliteal SLNs by staining with Evan's blue dye (Fig. 2B). To histologically evaluate the process of lymphangiogenesis, the anti-mouse LYVE-1 antibody was used to identify the lymphatic endothelium (20, 28). The absence of colocalization of LYVE-1 and CD31 staining was evident in the lymph node tissue (Fig. 3A-D ), confirming that LYVE-1 did not stain blood vessels in the lymph node. Normally, the lymph vessels/sinuses with an open lumen in the popliteal lymph node of young adult mice are not common. The collapsed lymphatic endothelium branching from the hilum to the medulla and paracortex of the lymph node is usually observed (Fig. 3E). In the popliteal SLNs for CNE-2 tumor-bearing mice, these lymph vessels/sinuses were clearly dilated (Figs. 3F and 4 ) before metastasis.


Figure 3
View larger version (83K):
[in this window]
[in a new window]
  		Figure 3. Identification of lymphatic channels in popliteal lymph nodes by using anti-LYVE-1 antibody. A to C, immunofluorescent images of the same lymph node section. A, staining with anti-LYVE-1 primary antibody followed by FITC-conjugated secondary antibody (green fluorescence). B, staining with anti-CD31 primary antibody followed by rhodamine-conjugated secondary antibody (red fluorescence). C, staining with DAPI blue fluorescence to indicate the nucleus. D, merged image of (A-C), showing no colocalization of LYVE-1 and blood vessels. E to G, images of routine immunohistochemical staining using anti-LYVE-1 antibody. E, a section of a normal popliteal lymph node. Inset, the higher magnification of the framed area. F, a section of a sentinel popliteal lymph node from a nude mouse 10 days after CNE-2 Clone-18 cell inoculation; enlargement of the lymph sinuses is evident. G, a section of a sentinel popliteal lymph node without metastasis from an immunocompetent BALB/c mouse 15 days after DA3 cell inoculation.

 

Figure 4
View larger version (131K):
[in this window]
[in a new window]
  		Figure 4. The enlargement of lymph sinuses and blood vessel lumens in the SLN before metastasis. The normal popliteal lymph nodes was collected from a 8-week-old female nude mouse without tumor cell inoculation. The contralateral and sentinel popliteal lymph nodes were collected from another mouse with the same age 20 days after tumor cell inoculation. Continuous sections from each lymph node were used for the lymphatic, blood vessel, and H&E staining. The lymphatic and blood vessel endothelia were stained using anti-LYVE-1 and anti-CD31 antibodies, respectively. H&E staining shows the RBC in the enlarged and functioning blood vessels in sentinel popliteal lymph node, in which enlargement of lymphatic sinuses is also evident. Bars, 0.1 mm.

 
To assess the correlation between lymph sinus dilation and primary tumor weight, 12 nonmetastatic sentinel popliteal lymph nodes from the nude mice carrying CNE-2 Clone-18 tumors 30 days after inoculation were studied. The largest cross-section of each lymph node stained with H&E was completely captured in several images (Supplementary Fig. S1A). The total lymph sinus area was then objectively calculated by the computer program (Supplementary Fig. S1B). The total area of lymph vessels/sinuses was significantly correlated with the primary tumor weight (Supplementary Fig. S1C), implying that the dilation of the lymph vessels/sinuses in SLN was induced by the primary tumor.

The HEV is responsible for tumor-induced vascularization in the lymph node. Histologic examination confirmed that the enlarged blood vessels in popliteal SLNs contained numerous RBC (Fig. 4), consistent with the functional ultrasonography analyses. Besides the typically thin, attenuated capillary vessels (<15 µm in diameter), HEVs (>20 µm in their largest diameter) were conspicuous in the normal mouse popliteal lymph node (Figs. 4 and 5A ), with their characteristically cuboidal endothelial cells expressing peripheral node addressin, which could be recognized by the MECA-79 antibody (Fig. 5B; refs. 29, 30) as well as by traditional blood vessel markers. Unlike lymph vessels/sinuses, which concentrate in and branch from the hilum to the medulla/paracortex, HEVs were evenly distributed in both medullary and paracortical regions in the mouse popliteal lymph node (Fig. 4). In the popliteal SLNs of mice bearing CNE-2 tumors, however, the HEVs were dilated, with increased lumenal diameter (Figs. 4 and 5D) and the branching out of thin-walled blood vessels (Fig. 5C). Few HEV with flattened lumens (like those in normal lymph nodes) were observed in the SLN 20 days after tumor cell inoculation.


Figure 5
View larger version (110K):
[in this window]
[in a new window]
  		Figure 5. Remodeling of HEVs in the SLN of animal models and in the regional lymph nodes of breast cancer patients is evident. Normal popliteal lymph nodes in BALB/c nude mice, stained with anti-CD31 antibody (A) and stained with anti-MECA79 antibody (B). Popliteal SLN before metastasis 10 days after Clone-18 inoculation, stained with anti-CD31 antibody (C) and stained with anti-MECA79 antibody (D). Remodeled HEVs are seen to be dilated and are branching out into thin-walled, functional blood vessels containing RBC (asterisks in C), which are typical of an angiogenic phenotype. E, human noncancerous axillary lymph node with a normal HEV (arrow). F to H, nonmetastatic axillary lymph nodes from breast cancer patients. F, a dilated HEV. G, a dilated and remodeled HEV with a part of the vessel wall transforming into thin wall (arrow). H, another transforming HEV with the changing of the high endothelial cells into flat endothelial cells (arrow). Staining is with anti-MECA79 antibody (E and F) and H&E (G and H).

 
The remodeling of HEV in SLN could be induced in nude mice carrying low-metastatic clones as well as in immunocompetent mice carrying syngeneic mouse breast cancer cells. To determine if the premetastatic lymphangiogenesis and vascularization observed in the murine SLNs are universal, we inoculated low-metastatic CNE-2 Clone-22 and Clone-26 cells into the immunodeficient mice and mouse breast adenocarcinoma DA3 cells into the immunocompetent BALB/c mice. The popliteal lymph nodes were collected 15 to 30 days after inoculation. The dilation of lymph sinuses/vessels was consistent with the findings from Clone-18 experiments (Fig. 3G). Computerized quantitative analyses were done to measure the HEV number, the wall thickness, and the adjusted cross-sectional lumen area of HEV. The mean HEV sections per field (0.26 mm2) of the popliteal SLNs versus the contralateral popliteal lymph node in the animal models of Clone-22, Clone-26, and DA3 tumors were 8.97 ± 2.3 versus 20.95 ± 5.75 (P < 0.001), 8 ± 2.1 versus 14.57 ± 3.7 (P < 0.001), and 9.65 ± 3.18 versus 14.9 ± 5.68 (P < 0.001), respectively. In these mouse models, the decrease of the HEV density in SLNs can be explained by the dilation of the HEV lumen, the dilation of the lymph sinuses, and the proliferation of the lymphocytes during lymphadenophathy. In all of these groups, the wall thickness of HEVs was significantly decreased in the SLNs, whereas the adjusted cross-sectional lumen area of HEVs was significantly increased (Fig. 6A and B ). These results suggest that the premetastasis remodeling of HEVs in SLNs is a common phenomenon in animal models and is independent to the metastatic ability of cancer cells.


Figure 6
View larger version (48K):
[in this window]
[in a new window]
  		Figure 6. Quantitative analyses of the remodeling of HEVs in both animal SLNs and human regional lymph nodes. A, the increase of the adjusted HEV lumen area in the sentinel popliteal lymph node before metastasis is statistically significant in nude mice carrying human cancers (CNE-2 Clone-22 and Clone-26) as well as in immunocompetent BALB/c mice carrying mouse DA3 breast adenocarcinoma (P < 0.001). B, the decrease of the HEV wall thickness is statistically significant in Clone-22 (P < 0.001), Clone-26 (P < 0.001), and DA3 (P = 0.035). C to F, immunohistochemical staining of HEVs using anti-MECA79 antibody in a human noncancerous lymph node from a cancer-free patient (C), a nonmetastatic lymph node from a breast cancer patient (D), and a metastatic lymph node (E and F) showing the margin of a metastatic tumor lesion (T in E) and a lymphoid tissue area distant to the tumor lesion (F). G, proportion of HEVs with lumens (any or >80 µm2) for control, nonmetastatic, and metastatic lymph nodes. *, P < 0.001 relative to control; **, P < 0.001 relative to nonmetastatic. H, proportion of open lumen HEVs with various wall thicknesses for control, nonmetastatic, and metastatic lymph nodes. *, P < 0.05 relative to control.

 
Remodeling of HEVs in the axillary lymph nodes of human breast cancer patients. To determine if the remodeling of HEVs also occurred in human neoplasia, we examined a series of archived axillary lymph node tissues. The normal thick-walled HEVs devoid of RBC were easily identified in human axillary lymph nodes (Fig. 5E). However, in the nonmetastatic axillary lymph nodes of breast cancer patients, the HEVs had increased lumen diameters, contained RBC, and transitioned into thin-walled enlarged blood vessels (Fig. 5F-H). To quantitatively evaluate these changes, 10 axillary lymph nodes from 6 patients with noncancerous chronic inflammation were used to generate 28 images of the regions of greatest HEV density ("hotspots") within the lymph node sections for a noncancerous control (Fig. 6C). Fourteen metastatic and 11 nonmetastatic axillary lymph nodes from 7 breast cancer patients were selected to generate 32 and 31 images of HEV hotspots, respectively (Fig. 6D-F).

The mean HEV sections per field (0.26 mm2) of metastatic, nonmetastatic, and noncancerous control lymph nodes were 20.21 ± 7.22, 24.44 ± 10.25, and 36.69 ± 15.94, respectively. The difference between the mean HEV numbers per field in metastatic versus nonmetastatic lymph nodes in breast cancer patients was statistically significant (P = 0.00004). The difference in the mean HEV numbers per field between metastatic versus control lymph nodes, as well as between nonmetastatic versus control lymph nodes, was likewise statistically significant (P = 0.0014 and 0.0315, respectively).

The mean adjusted cross-sectional lumen areas for images of metastatic, nonmetastatic, and noncancerous control lymph nodes were 215.44 ± 491.20, 156.84 ± 301.41, and 34.70 ± 30.52 µm2, respectively. The difference between the mean adjusted lumen area in metastatic versus nonmetastatic lymph node sections was not statistically significant (P = 0.26). The difference in the mean adjusted lumen cross-sectional area between images of metastatic versus noncancerous control lymph node, as well as between nonmetastatic versus noncancerous control lymph nodes, was statistically significant (P < 0.00001 for each).

Of particular interest was the measurement of the emergence of functional venules from the population of nascent HEVs. We selected 80 µm2 as a minimum luminal cross-sectional area for functional vessels, corresponding to the minimum caliber of physiologic venules (31). Figure 6G compares the proportion of HEVs having any measurable open lumen at all, as well as those with open lumens of at least 80 µm2, among metastatic, nonmetastatic, and noncancerous control nodes. Significantly more vessels had open lumens among the HEVs imaged in metastatic lymph nodes (38%) relative to both nonmetastatic lymph node (27%) and noncancerous control lymph nodes (11%; P < 0.001 for each), as well as among nonmetastatic (27%) relative to noncancerous control lymph node (11%; P < 0.001). Similarly, the proportion of HEVs with adjusted luminal areas of at least 80 µm2 was significantly larger in metastatic lymph nodes (18%) compared with both nonmetastatic (13%) and noncancerous control lymph nodes (0.8%; P < 0.001 for each), as well as among nonmetastatic (13%) relative to noncancerous control lymph nodes (0.8%; P < 0.001).

Comparing the proportion of vessels with any open lumen at all which exceeded the theoretical minimum caliber for function (80 µm2), there was no significant difference between the metastatic lymph node (47%) and nonmetastatic lymph node (45%; P = 0.8). However, the difference between each of these groups and the noncancerous control lymph node (8%) was highly significant (P < 0.00001 for both).

Among HEVs with open lumens, the mean estimated vessel wall thickness for HEVs imaged in noncancerous control, nonmetastatic, and metastatic lymph nodes was 11.96 ± 3.93, 8.57 ± 3.52, and 9.12 ± 4.80 µm, respectively. Whereas there was no significant difference between mean HEV wall thickness in metastatic and nonmetastatic nodes (P = 0.14), the mean wall thickness for each group was significantly thinner than in noncancerous control nodes (P < 0.00001 for both).

Figure 6H compares the wall thicknesses of those HEVs that had open lumens among noncancerous control, nonmetastatic, and metastatic lymph nodes. There was no difference in the proportion of HEVs with walls <5-µm thick between metastatic (9.8%) and nonmetastatic nodes (7.4%) or between nonmetastatic and control lymph nodes (2.5%), but there was a significantly larger proportion of HEVs with walls <5-µm thick when comparing metastatic to control lymph nodes (P = 0.035). Furthermore, there was no difference in the proportion of HEVs with walls 5- to 10-µm thick or 10- to 15-µm thick when comparing metastatic (59% and 22%, respectively) and nonmetastatic lymph nodes (63% and 23%, respectively). However, each of these groups had a significantly greater proportion of HEVs with walls 5- to 10-µm thick and a significantly smaller proportion with walls 10- to 15-µm thick relative to noncancerous controls (29% and 49%, respectively; P < 0.0001 for all).

Finally, there was a significantly larger proportion of HEVs with walls >15-µm thick in the control lymph node (18%) relative to either the metastatic (8%; P = 0.006) or nonmetastatic lymph node (6%; P = 0.0018). There was an inverse correlation between lumen size and wall thickness for those vessels that have lumens (Spearman's {rho} = –0.318; P < 0.0001), implying that the larger the HEV lumen, the thinner the vessel wall. All these results suggested that, in human axillary lymph nodes of breast cancer patients, the remodeling of HEV started before metastasis and continued after the arrival of metastatic cancer cells. The decrease of HEV density in the cancerous condition can be explained by the dramatic dilation of the HEV lumen space.

Proliferation of endothelial cells during the remodeling of HEV. For the proliferation study in mouse lymph node, 10 normal mouse popliteal lymph nodes were collected at the age of 2 months old. Ten nonmetastatic and 10 metastatic mouse sentinel popliteal lymph nodes were also collected from nude mice 30 days after inoculation of CNE-2 Clone-18 cells into the left hind footpads. The combined fluorescent images of triple stained HEVs were used to calculate the proliferation rates of HEV endothelial cells (Fig. 7A ). The proliferation rate of HEV endothelial cells was significantly increased before metastasis (Fig. 7E), which is consistent with the process of HEV remodeling. The endothelial cell proliferation rates were not different between nonmetastatic and metastatic lymph nodes, implying that the proliferation of HEV endothelial cells was mainly influenced by the duration of the cancerous condition.


Figure 7
View larger version (102K):
[in this window]
[in a new window]
  		Figure 7. Proliferation of the HEV endothelial cells was involved in the morphologic and functional alterations of HEVs. A and B, combined images of triple immunofluorescent staining on MECA79 (green), proliferating marker PCNA (red), and nuclei (blue). Arrows, proliferating endothelial cells in the HEVs. A, a nonmetastatic sentinel popliteal lymph node section from a nude mouse bearing a CNE-2 Clone-18 tumor. B, a nonmetastatic axillary lymph node section from a breast cancer patient. C and D, the same area of two consecutive sections of a human metastatic lymph node tissue from a breast cancer patient. C, immunohistochemical staining of MECA79 indicating HEVs. D, immunohistochemical staining of PCNA indicating proliferating cells. Inset, enlarges one of the HEVs, showing two proliferating endothelial cells stained in brown (arrows). E, proliferation rates of HEV endothelial cells in mouse lymph nodes. F, proliferating rate of HEV endothelial cells in the human lymph nodes. Columns, mean; bars, SD. *, P < 0.001 relative to control; **, P < 0.001 relative to the nonmetastatic group.

 
To confirm that proliferation of HEV endothelial cells is also involved in the remodeling process of human HEV, the above-mentioned 10 noncancerous, 11 nonmetastatic, and 14 metastatic axillary lymph nodes from patients were immunofluorescently stained (Fig. 7B). The typical proliferating HEV endothelial cells in a metastatic lymph node detected by routine immunohistochemical staining are also shown in Fig. 7C and D. The proliferation rate of the HEV endothelial cells was significantly increased in the nonmetastatic lymph nodes (Fig. 7F), which was consistent with our results from animal models. Interestingly, the proliferation rate of HEV endothelial cells was significantly higher in the metastatic human lymph nodes than in nonmetastatic lymph nodes, implying that the lymph nodes with more robust HEV proliferation may be associated with a higher metastasis possibility in human lymph node.

Characteristics of endotoxin-induced lymphadenopathy and tumor-reactive lymphadenopathy. The use of athymic nude mice, which lack T cells, clearly excludes the possibility that node proliferation is due to the generation of a primary immune response to micrometastases or to tumor antigens from the primary lesion being presented by antigen-presenting cells arriving via the afferent lymphatics. The use of DA3 cells in the syngeneic BALB/c mice further excludes the involvement of immune response. However, the injection of dead CNE-2 Clone-18 cells fixed with 70% alcohol (8 x 104 cells twice with a 5-day interval), saline (30 µL daily for 20 days), or the serum from nude mice carrying CNE-2 tumors (30 µL daily for 20 days) all failed to induce any morphologic and functional alteration of the lymph channel or HEV vasculature in the SLNs (data not shown). Moreover, in any of our footpad models, we found no morphologic alteration of the lymph channel or HEV vasculature in the second lymph node station (e.g., the inguinal lymph nodes; data not shown).

It is unclear whether morphologic alterations of the lymph channel and HEV vasculature share the same patterns in inflammatory lymphadenopathy and tumor-reactive lymphadenopathy. In nude mice, the absence of T cells accounts for the resistance to endotoxin-induced inflammation (32, 33). Therefore, prolonged administration of endotoxin for 20 days was done to induce significant lymphadenopathy in the sentinel popliteal lymph node (Supplementary Fig. S1D). Staining for LYVE-1 showed that the dilated lymph vessels/sinuses in endotoxin-induced lymphadenopathy were full of lymphocytes (Supplementary Fig. S1E). This was in contrast to the dilated lymph vessels/sinuses in tumor-reactive lymphadenopathy, which contained few cellular structures, implying that it was carrying a large amount of fluid rather than a large amount of lymphocytes. Interestingly, the morphology of HEVs was not altered at all in the endotoxin-induced lymphadenopathy (Supplementary Fig. S1E), suggesting that the inflammatory reaction and cancerous reaction in the SLN are induced by different mechanisms.

Premetastatic remodeled HEVs could integrate into the postmetastatic tumor vasculature with further differentiation. The standard marker for HEVs is MECA-79. The MECA-79-reactive ligand is known as peripheral node addressin (PNAd). Anti-MECA-79 antibody specifically stains HEVs in lymph nodes and other secondary lymphoid organs in many species, including humans and mice (34). Within metastatic tumor nests in the axillary lymph nodes from human breast cancer patients, some indentified HEVs were full of RBC, implying fully functioning vessels (Supplementary Fig. S2A). Interestingly, the remodeled HEVs gradually lost their specific marker MECA-79 from the tumor margin to the central portion of the tumor nests (Supplementary Fig. S2B), implying further differentiation of the HEVs when they integrated into the metastatic tumor vasculature. Actually, most of the HEVs lost their specific marker MECA-79 after integrating into the tumor vasculature, leaving the surrounding remnant lymphoid tissue, indicating that they were pre-existing vessels (Supplementary Fig. S2C). These findings implied that the remodeled HEVs in the premetastatic phase continued to nurture the metastatic lesions after the arrival of cancer cells and therefore played an important role in the secondary tumor growth inside the involved lymph node.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The lumens of the lymph sinuses/vessels were dilated in SLN before metastasis. The SLN is rebuilt by the primary tumor to become a functional blood vessel–enriched organ before and independent of metastasis, with the morphologic and functional alterations of the HEVs to become main blood flow carrier in the lymph node. The processes of vascularization in the SLN were consistent in both animal model and human tissues. This study presents functional and structural data that the primary tumor is manipulating the "soil" to improve the "seeding" of subsequent metastases.

The extent of lymph sinus dilation in the SLN was significantly correlated with the primary tumor weight, suggesting that the lymph from the primary tumor induced the persistent alteration of the lymph channel in SLN. These results are consistent with a recent finding that, in contrast to angiogenesis, in which blood flow proceeds only after the vessel develops, lymphangiogenesis can be induced by interstitial fluid channeling (35). The alteration of lymph channels in SLNs can also occur during an inflammatory reaction, which facilitates the migration of inflammatory cells (36). Interestingly, the dilated lymph vessels/sinuses in endotoxin-induced lymphadenopathy were full of lymphocytes, but they contained very few cellular structures in tumor-reactive lymphadenopathy, suggesting different roles of the SLN lymphatic channels in different pathologic processes.

It has been well characterized that the HEVs of lymph nodes play an important role in recruiting lymphocytes for the generation of immune responses. By expressing homing receptors on their surface, which blood lymphocytes can recognize as they pass in circulation, HEVs provide a unique location where naive lymphocytes can enter the lymph node (30, 37, 38). In this study, we found that the role of HEV was shifted to become the main blood flow carrier in the SLN before metastasis. Not only could the HEV morphology change dramatically to carry more blood flow, but the proliferation rate of HEV endothelial cells was also increased before metastasis. However, the HEV morphology did not alter at all in endotoxin-induced lymphadenopathy, implying a selective reaction of HEV in the cancerous condition.

The adaptive response of the vascular wall has been noted when a vein segment is transposed as a bypass graft into the arterial circulation, with an increase in wall thickness and the appearance of multiple cellular layers in the venous endothelium (39, 40). Distinct, differentiated gene expression has also been reported when the endothelial cells respond to the changing of their microenvironment (41). In our own study, we found that the cellular morphology of the tall endothelial cells forming HEVs changed dramatically to become flat endothelial cells in cancerous condition. As a consequence, the HEV was remodeled from a thick-walled, endothelial vessel with a small lumen to a thin-walled, large-lumen vessel, shifting its function from recruiting lymphocytes to becoming a blood flow carrier. These facts suggest again that the blood vessel endothelium has tremendous potential to adapt its biomechanical environment.

The confined lymph and blood channel alterations within the SLN but not in the next station lymph node imply that an inducer from the primary tumor is functioning locally with the existence of a liable primary tumor. VEGF-A has been found to be an inducer of lymphangiogenesis in SLNs (9). We also found that the serum level of VEGF-A was elevated in patients with late-stage NPC (42). Because VEGF-A is a secreted protein that can travel via the bloodstream to other lymph nodes, our findings suggest that other inducers besides VEGF-A may be involved.

It is also of interest to explore the role of HEVs after the establishment of a metastatic tumor nest. We found that the enlarged, remodeled HEVs could integrate into the metastatic tumor vasculature with further differentiation, characterized by the gradual loss of their specific marker MECA-79 from the tumor margin to the central part of the metastatic tumor nest. It has been explained that, compared with primary tumors, the more rapid growth of metastatic lesions in the cervical lymph nodes of NPC patients was due to clonal selection of the cancer cells during metastases, with highly proliferative clones disseminated to the cervical nodes. However, based on our findings, the metastatic tumor vasculature in lymph nodes consists of many large blood vessels derived from normal HEVs, suggesting that the efficiency of nutrition and oxygen supplies could be better for the metastatic tumor cells in the involved lymph node. The enrichment of the blood supply in the lymph node before and after metastasis may favor the growth of newly arriving metastatic cancer cells. Consequently, the involved regional lymph nodes may become manifest, whereas the primary tumors remain clinically occult for years (43, 44). Moreover, the high density of functioning blood vessels in lymph nodes may subsequently facilitate the metastasis of cancer cell to distant organs. It will be important to elucidate if the highly vascularized premetastatic SLN is associated with an increased metastatic potential. Control of lymphatic fluid movement may also be a target to consider in preventing metastases.

In conclusion, our study reveals the basis of lymphangiogesis and angiogenesis within SLNs. The lumens of the lymph sinuses/vessels were dilated in SLNs before metastasis. The SLN was rebuilt by the primary tumor to become a functional blood vessel–enriched organ before and independent of metastasis, with morphologic and functional alterations of the HEVs to become the main blood flow carrier in the lymph node. The processes of vascularization in the SLN were consistent in both animal model and human tissues. This is the evidence that tumor-induced vascularization can be a regional process rather than purely a local event.


   Acknowledgments
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dawna Dylewski, Elissa Boguslawski, Bryn Eagleson, and the rest of the VARI vivarium staff for assistance in animal husbandry; JC Goolsby and the rest of the VARI Histology Core Facility for technical support; and David Nadziejka for critically reading this article.


   Footnotes
 
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Received 8/15/06. Accepted 8/18/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Johnson JT. A surgeon looks at cervical lymph nodes. Radiology 1990;175:607–10.[Abstract/Free Full Text]
  2. Ioachim HLRH. Tumor-reactive lymphadenopathy. 3rd ed. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo: Lippincott Williams and Wilkins; 2002. p. 254–8.
  3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15–8.[Medline]
  4. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002;62:1315–20.[Abstract/Free Full Text]
  5. Maula SM, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003;63:1920–6.[Abstract/Free Full Text]
  6. Pepper MS, Tille JC, Nisato R, Skobe M. Lymphangiogenesis and tumor metastasis. Cell Tissue Res 2003;314:167–77.[CrossRef][Medline]
  7. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192–8.[CrossRef][Medline]
  8. Cao R, Bjorndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004;6:333–45.[CrossRef][Medline]
  9. Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005;201:1089–99.[Abstract/Free Full Text]
  10. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002;13:1007–15.[Abstract/Free Full Text]
  11. Sham JS, Choy D, Wei WI. Nasopharyngeal carcinoma: orderly neck node spread. Int J Radiat Oncol Biol Phys 1990;19:929–33.[Medline]
  12. Carlson RW, Anderson BO, Bensinger W, et al. NCCN practice guidelines for breast cancer. Oncology (Huntingt) 2000;14:33–49.
  13. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001;19:3817–27.[Free Full Text]
  14. Rosen PP, Saigo PE, Braun DW, Jr., Weathers E, DePalo A. Predictors of recurrence in stage I (T1N0M0) breast carcinoma. Ann Surg 1981;193:15–25.[Medline]
  15. Sizhong Z, Xiukung G, Yi Z. Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer 1983;31:587–90.[Medline]
  16. Keshtgar MW, Lakhani W, Ell S. P. Dosimetry and radiation protection. Berlin: Springer; 1999. p. 91–102.
  17. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50–6.[CrossRef][Medline]
  18. Tsarfaty G, Stein GY, Moshitch-Moshkovitz S, et al. HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met. Neoplasia 2006;8:344–52.[CrossRef][Medline]
  19. Kort EJ, Campbell B, Resau JH. A human tissue and data resource: an overview of opportunities, challenges, and development of a provider/researcher partnership model. Comput Methods Programs Biomed 2003;70:137–50.[CrossRef][Medline]
  20. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999;144:789–801.[Abstract/Free Full Text]
  21. Ridler T, Calvard S. Picture thresholding using an iterative selection method. IEEE Transactions on Systems, Man, and Cybernet 1978;8:629–32.
  22. Kort EJ, Jones A, Daumbach M, et al. Quantifying cell scattering: the blob algorithm revisited. Cytometry. Part A: The Journal of the International Society for Analytical Cytology 2003;51:119–26.
  23. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003;3:453–8.[CrossRef][Medline]
  24. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893–5.[Abstract/Free Full Text]
  25. Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 2003;113:821–3.[CrossRef][Medline]
  26. Yang WT, Chang J, Metreweli C. Patients with breast cancer: differences in color Doppler flow and gray-scale U.S. features of benign and malignant axillary lymph nodes. Radiology 2000;215:568–73.[Abstract/Free Full Text]
  27. Lu W, Schroit AJ. Vascularization of melanoma by mobilization and remodeling of preexisting latent vessels to patency. Cancer Res 2005;65:913–8.[Abstract/Free Full Text]
  28. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001;22:317–21.[CrossRef][Medline]
  29. Hauff P, Reinhardt M, Briel A, Debus N, Schirner M. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: a feasibility study in mice and dogs. Radiology 2004;231:667–73. Epub 2004 Apr 29.[Abstract/Free Full Text]
  30. Yeh JC, Hiraoka N, Petryniak B, et al. Novel sulfated lymphocyte homing receptors and their control by a Core1 extension ß 1,3-N-acetylglucosaminyltransferase. Cell 2001;105:957–69.[CrossRef][Medline]
  31. Gartner LP, Hiatt JL. Color textbook of histology. 2nd ed. Philadelphia (PA): WB Saunders Company; 2001. p. 266.
  32. Huang JH, Lin YY, Lai YY, Hu SW. Lethal outcome caused by Porphyromonas gingivalis A7436 in a mouse chamber model is associated with elevated titers of host serum interferon-{gamma}. Oral Microbiology and Immunology 2006;21:100–6.[CrossRef][Medline]
  33. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-{gamma} production by T cells. Nature 1995;378:88–91.[CrossRef][Medline]
  34. Uchimura K, Gauguet JM, Singer MS, et al. A major class of L-selectin ligands is eliminated in mice deficient in two sulfotransferases expressed in high endothelial venules. Nat Immunol 2005;6:1105–13.[CrossRef][Medline]
  35. Boardman KC, Swartz MA. Interstitial flow as a guide for lymphangiogenesis. Circ Res 2003;92:801–8.[Abstract/Free Full Text]
  36. Halin C, Detmar M. An unexpected connection: lymph node lymphangiogenesis and dendritic cell migration. Immunity 2006;24:129–31.[CrossRef][Medline]
  37. Sackstein R. Physiologic migration of lymphocytes to lymph nodes following bone marrow transplantation: role in immune recovery. Semin Oncol 1993;20:34–9.[Medline]
  38. von Andrian UH, M'Rini C. In situ analysis of lymphocyte migration to lymph nodes. Cell Adhes Commun 1998;6:85–96.[Medline]
  39. Garrett HE, Diethrich EB, DeBakey ME. Myocardial revascularization. Surg Clin North Am 1966;46:863–71.[Medline]
  40. Kwei S, Stavrakis G, Takahas M, et al. Early adaptive responses of the vascular wall during venous arterialization in mice. Am J Pathol 2004;164:81–9.[Abstract/Free Full Text]
  41. Chi JT, Chang HY, Haraldsen G, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 2003;100:10623–8. Epub 2003 Sep 8.[Abstract/Free Full Text]
  42. Qian CN, Zhang CQ, Guo X, et al. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 2000;88:255–61.[CrossRef][Medline]
  43. Medina-Franco H, Urist MM. Occult breast carcinoma presenting with axillary lymph node metastases. Rev Invest Clin 2002;54:204–8.[Medline]
  44. Nieder C, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma. Curr Treat Options Oncol 2002;3:33–40.[Medline]



This article has been cited by other articles:


Home page
 Ann OncolHome page
T. Donnem, S. Al-Saad, K. Al-Shibli, L.-T. Busund, and R. M. Bremnes
Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer
Ann. Onc., July 23, 2009; (2009) mdp296v1.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Ma and D. J. Waxman
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. G. Van den Eynden, M. K. Vandenberghe, P.-J. H. van Dam, C. G. Colpaert, P. van Dam, L. Y. Dirix, P. B. Vermeulen, and E. A. Van Marck
Increased Sentinel Lymph Node Lymphangiogenesis is Associated with Nonsentinel Axillary Lymph Node Involvement in Breast Cancer Patients with a Positive Sentinel Node
Clin. Cancer Res., September 15, 2007; 13(18): 5391 - 5397.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. J. Bruxvoort, H. M. Charbonneau, T. A. Giambernardi, J. C. Goolsby, C.-N. Qian, C. R. Zylstra, D. R. Robinson, P. Roy-Burman, A. K. Shaw, B. D. Buckner-Berghuis, et al.
Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Cancer Res., March 15, 2007; 67(6): 2490 - 2496.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. K. Jain, R. T. Tong, and L. L. Munn
Effect of Vascular Normalization by Antiangiogenic Therapy on Interstitial Hypertension, Peritumor Edema, and Lymphatic Metastasis: Insights from a Mathematical Model
Cancer Res., March 15, 2007; 67(6): 2729 - 2735.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-06-2977v1
66/21/10365    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qian, C.-N.
Right arrow Articles by Teh, B. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qian, C.-N.
Right arrow Articles by Teh, B. T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online